PEPTIDEREPORT

Video claim watch

Peptides: The Science, Uses & Safety | Dr. Abud Bakri

Large-audience peptide safety conversation that can influence mainstream questions and category-level search demand.

Andrew Huberman channel2:48:23 runtime416K views when checked

Published Jun 1, 2026. Metadata checked Jun 30, 2026.

Watch on YouTube

Transcript review

6 material claims logged

Published with source gaps audit stateauto-captioned transcript0 operational-guidance flags0 source gaps

Reviewed Jul 12, 2026. Next review Aug 12, 2026.

major reach and many testable claims; several legal-status statements are imprecise or wrong.

auto-caption available; 28 creator chapters.

Claim-by-claim audit

What the video says, and what needs checking

01:07:25
High-risk evidence claimHigh-risk safety claim

Discusses Pinealon/Epithalon sleep, cognition, DNA repair and longevity claims; 01:29:53 covers TB-500/thymic compounds; 01:50:33 GHK-Cu; 02:04:01 secretagogues; 02:33:53 retatrutide.

Review topic: multiple unapproved peptides.

Checked against: FDA BPC-157 compounding safety risk: immunogenicity

compound-specific registries; no category-level extrapolation.

Connected research

Compounds discussed

Retatrutide Retatrutide has produced large weight reductions in randomized Phase 2 and Phase 3 trials, but it remains unapproved. Long-term outcomes, direct comparisons, rare risks, durability, and final regulatory decisions remain unresolved. BPC-157 BPC-157 is an experimental peptide with extensive animal research but very limited human evidence. A Phase 1 registry record has no posted efficacy result, and a small uncontrolled knee-pain report does not establish benefit. It is not FDA-approved and is prohibited in sport. GHK-Cu GHK-Cu is a copper-binding tripeptide studied mainly in topical skin contexts. In the reviewed sources, one small randomized human study found no objective advantage after laser resurfacing, a Phase 2 topical-wound trial is still recruiting, and comparable human evidence for injectable or systemic claims was not identified. TB-500 TB-500 is marketed as a thymosin-beta-4-related recovery peptide. The sources currently linked to this profile are regulatory records, not human efficacy studies. It is not FDA-approved and was scheduled for FDA advisory committee discussion in July 2026. Epitalon Epitalon is a synthetic tetrapeptide promoted for longevity and telomere-related effects. The reviewed evidence rests largely on cell studies and publications from one Russian research group. Large, independently replicated human trials have not established an anti-aging benefit.

Source check

Records used in this claim audit

TRIUMPH-1: retatrutide in participants with obesity or overweight

ClinicalTrials.gov · Primary regulatory · Jul 3, 2023 · accessed Jul 12, 2026

Completed Phase 3 master protocol NCT05929066. The registry identifies TRIUMPH-1 as a randomized, double-blind, placebo-controlled study in adults without type 2 diabetes who have obesity or overweight.

12 linked pagesOpen original · clinicaltrials-retatrutide-triumph1

PCO-02 safety and pharmacokinetics trial

ClinicalTrials.gov · Primary regulatory · Dec 22, 2015 · accessed Jul 12, 2026

Registry record for a Phase 1 safety and pharmacokinetics study associated with BPC-157. The record status is unknown and no efficacy result is posted.

6 linked pagesOpen original · clinicaltrials-bpc157-pco02